GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » Debt-to-EBITDA

Heska (HSKA) Debt-to-EBITDA : -5.22 (As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Heska Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Heska's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $4.0 Mil. Heska's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $105.4 Mil. Heska's annualized EBITDA for the quarter that ended in Mar. 2023 was $-21.0 Mil. Heska's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was -5.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Heska's Debt-to-EBITDA or its related term are showing as below:

HSKA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -61.62   Med: 0.47   Max: 13.86
Current: -61.62

During the past 13 years, the highest Debt-to-EBITDA Ratio of Heska was 13.86. The lowest was -61.62. And the median was 0.47.

HSKA's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.21 vs HSKA: -61.62

Heska Debt-to-EBITDA Historical Data

The historical data trend for Heska's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heska Debt-to-EBITDA Chart

Heska Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 9.71 13.86 7.38 -28.03

Heska Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.58 -13.43 7.00 15.01 -5.22

Competitive Comparison of Heska's Debt-to-EBITDA

For the Medical Devices subindustry, Heska's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heska's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heska's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Heska's Debt-to-EBITDA falls into.



Heska Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Heska's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.944 + 100.125) / -3.677
=-28.03

Heska's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.049 + 105.383) / -20.952
=-5.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2023) EBITDA data.


Heska  (NAS:HSKA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Heska Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Heska's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Heska (HSKA) Business Description

Traded in Other Exchanges
N/A
Address
3760 Rocky Mountain Avenue, Loveland, CO, USA, 80538
Heska Corp is engaged in developing, manufacturing, marketing, selling, and supporting veterinary products. The company's products include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products; and practice information management software and related software. It operates through two segments North America and International. The Company's core strategic focus on Point of Care laboratory and imaging products is included in both segments.
Executives
Joachim A. Hasenmaier director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Robert L Antin director
Mark F Furlong director 770 M WATER ST, MILWAUKEE WI 53202
Stephen L Davis director 2901 BUTTERFIELD ROAD, OAK BROOK IL 60523
Providenti Anthony C. Jr. officer: EVP, Corporate Development 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Kevin S. Wilson officer: President and COO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Eleanor F. Baker officer: EVP, Managing Dir. & COO, scil 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Christopher D. Sveen officer: CAO & General Counsel 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Nancy Wisnewski officer: EVP, Prod. Dev. & Cust. Supp 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Sharon L. Riley director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Catherine Grassman officer: EVP, CFO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason D Aroesty officer: EVP, International Diagnostics 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Bonnie J. Trowbridge director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Scott Humphrey director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason A Napolitano officer: Exec. VP, CFO & Secretary 1613 PROSPECT PARKWAY, FORT COLLINS CO 80525